Stereotactic body radiation therapy for low- and low-intermediate-risk prostate cancer: Is there a dose effect?

Frontiers in Oncology

Volumn 1, Issue DEC, 2011, Pages

  Katz, Alan J ^a   Santoro, Michael ^a   Ashley, Richard ^b   Diblasio, Ferdinand ^c  

^a Flushing Radiation Oncology   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c Mount Sinai Doctors   (United States)

Author keywords

ratio; CyberKnife; Dose; Prostate; Stereotactic body radiation therapy

Indexed keywords

EID: 84887112174     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00049     Document Type: Article

References (43)

1. Alcantara, P., Hanlon, A., Buyyounouski, M. K., Horwitz, E. M., and Pollack, A. (2007). Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109, 41-47.
2. Boike, T. P., Lotan, Y., Cho, L. C., Brindle, J., Derose, P., Xie, X. J., Yan, J., Foster, R., Pistenmaa, D., Perkins, A., Cooley, S., and Timmerman, R. (2011). Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. J. Clin. Oncol. 29, 2020-2026.
3. Bolzicco, G., Favretto, M. S., Scremin, E., Tambone, C., Tasca, A., and Guglielmi, R. (2010). Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol. Cancer Res. Treat. 9, 473-477.
4. Brenner, D. J., and Hall, E. J. (1999). Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 43, 1095-1101.
5. Brenner, D. J., Martinez, A. A., Edmundson, G. K., Mitchell, C., Thames, H. D., and Armour, E. P. (2002). Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int. J. Radiat. Oncol. Biol. Phys. 52, 6-13.
6. Cahlon, O., Zelefsky, M. J., Shippy, A., Chan, H., Fuks, Z., Yamada, Y., Hunt, M., Greenstein, S., and Amols, H. (2008). Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int. J. Radiat. Oncol. Biol. Phys. 71, 330-337.
7. Cox, J. D., Stetz, J., and Pajak, T. F. (1995). Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 31, 1341-1346.
8. Fowler, J., Chappell, R., and Ritter, M. (2001). Is alpha/beta for prostate tumors really low? Int. J. Radiat. Oncol. Biol. Phys. 50, 1021-1031.
9. Fowler, J. F. (2005). The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 44, 265-276.
10. Fowler, J. F., Ritter, M. A., Chappell, R. J., and Brenner, D. J. (2003). What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 56, 1093-1104.
11. Freeman, D. E., and King, C. R. (2011). Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat. Oncol. 6, 3.
12. Friedland, J. L., Freeman, D. E., Masterson-Mcgary, M. E., and Spellberg, D. M. (2009). Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol. Cancer Res. Treat. 8, 387-392.
13. Fuller, D. B. (2008). CyberKnife Radiosurgery For Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry. Available at: http://clinicaltrials.gov/ct2/show/NCT00643617
14. Fuller, D. B., Mardirossian, G., Wong, D., and Mckellar, H. (2010). Prospective evaluation of stereotactic radiotherapy for low and intermediate risk prostate cancer: emulating HDR brachytherapy dose distribution. Int. J. Radiat. Oncol. Biol. Phys. 78, S358-S359.
15. Gagnon, G. J., Nasr, N. M., Liao, J. J., Molzahn, I., Marsh, D., Mcrae, D., and Henderson, F. C. Sr. (2009). Treatment of spinal tumors using cyberknife fractionated stereotactic radiosurgery: pain and quality-of-life assessment after treatment in 200 patients. Neurosurgery 64, 297-306; discussion 306-297.
16. Grimm, P. D., Blasko, J. C., Sylvester, J. E., Meier, R. M., and Cavanagh, W. (2001). 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 51, 31-40.
17. Hanks, G. E., Hanlon, A. L., Pinover, W. H., Horwitz, E. M., Price, R. A., and Schultheiss, T. (2000). Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int. J. Radiat. Oncol. Biol. Phys. 46, 823-832.
18. Jabbari, S., Weinberg, V. K., Kaprealian, T., Hsu, I. C., Ma, L., Chuang, C., Descovich, M., Shiao, S., Shinohara, K., Roach, M. III, and Gottschalk, A. R. (2010). Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int. J. Radiat. Oncol. Biol. Phys. (in press).
19. Katz, A. J., Santoro, M., Ashley, R., Diblasio, F., and Witten, M. (2010). Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 10, 1. doi:10.1186/1471-2490-10-1
20. King, C. R., Brooks, J. D., Gill, H., Pawlicki, T., Cotrutz, C., and Presti, J. C. Jr. (2009). Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 73, 1043-1048.
21. King, C. R., and Fowler, J. F. (2001). A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int. J. Radiat. Oncol. Biol. Phys. 51, 213-214.
22. Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., Lee, A. K., and Pollack, A. (2008). Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 67-74.
23. Kupelian, P., Kuban, D., Thames, H., Levy, L., Horwitz, E., Martinez, A., Michalski, J., Pisansky, T., Sandler, H., Shipley, W., Zelefsky, M., and Zietman, A. (2005). Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int. J. Radiat. Oncol. Biol. Phys. 61, 415-419.
24. Kupelian, P. A., Potters, L., Khuntia, D., Ciezki, J. P., Reddy, C. A., Reuther, A. M., Carlson, T. P., and Klein, E. A. (2004). Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 25-33.
25. Lamb, D. S., Denham, J. W., Joseph, D., Matthews, J., Atkinson, C., Spry, N. A., Duchesne, G., Ebert, M., Steigler, A., Delahunt, B., and D'este, C. (2011). A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 79, 385-391.
26. Martin, A., and Gaya, A. (2010). Stereotactic body radiotherapy: a review. Clin. Oncol. (R. Coll. Radiol.) 22, 157-172.
27. Martinez, A. A., Demanes, J., Vargas, C., Schour, L., Ghilezan, M., and Gustafson, G. S. (2009). High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am. J. Clin. Oncol. 33, 481-488.
28. Martinez, A. A., Pataki, I., Edmundson, G., Sebastian, E., Brabbins, D., and Gustafson, G. (2001). Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int. J. Radiat. Oncol. Biol. Phys. 49, 61-69.
29. Meier, R., Beckman, A., Kaplan, I., Mohideen, N., Shieh, E., Henning, G., Walz, B., Cotrutz, C., and Sanda, M. (2010). Stereotactic radiotherapy for organ-confined prostate cancer: early toxicity and quality of life outcomes from a multi-institutional trial. Int. J. Radiat. Oncol. Biol. Phys. 78, S57.
30. Miralbell, R., Roberts, S. A., Zubizarreta, E., and Hendry, J. H. (2011). Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta=1.4 (0.9-2.2) Gy. Int. J. Radiat. Oncol. Biol. Phys. (in press).
31. Pollack, A., Zagars, G. K., Starkschall, G., Antolak, J. A., Lee, J. J., Huang, E., Von Eschenbach, A. C., Kuban, D. A., and Rosen, I. (2002). Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53, 1097-1105.
32. Ray, M. E., Thames, H. D., Levy, L. B., Horwitz, E. M., Kupelian, P. A., Martinez, A. A., Michalski, J. M., Pisansky, T. M., Shipley, W. U., Zelefsky, M. J., Zietman, A. L., and Kuban, D. A. (2006). PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int. J. Radiat. Oncol. Biol. Phys. 64, 1140-1150.
33. Roach, M. III, Hanks, G., Thames, H. Jr., Schellhammer, P., Shipley, W. U., Sokol, G. H., and Sandler, H. (2006). Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65, 965-974.
34. Rusthoven, K. E., Kavanagh, B. D., Cardenes, H., Stieber, V. W., Burri, S. H., Feigenberg, S. J., Chidel, M. A., Pugh, T. J., Franklin, W., Kane, M., Gaspar, L. E., and Schefter, T. E. (2009). Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27, 1572-1578.
35. Stock, R. G., Klein, T. J., Cesaretti, J. A., and Stone, N. N. (2009). Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 74, 753-758.
36. Stone, N. N., Stock, R. G., Cesaretti, J. A., and Unger, P. (2010). Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int. J. Radiat. Oncol. Biol. Phys. 76, 355-360.
37. Svedman, C., Karlsson, K., Rutkowska, E., Sandstrom, P., Blomgren, H., Lax, I., and Wersall, P. (2008). Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 47, 1578-1583.
38. Timmerman, R., Paulus, R., Galvin, J., Michalski, J., Straube, W., Bradley, J., Fakiris, A., Bezjak, A., Videtic, G., Johnstone, D., Fowler, J., Gore, E., and Choy, H. (2010). Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303, 1070-1076.
39. Townsend, N. C., Huth, B. J., Ding, W., Garber, B., Mooreville, M., Arrigo, S., Lamond, J., and Brady, L. W. (2011). Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am. J. Clin. Oncol. 34, 6-10.
40. Wei, J. T., Dunn, R. L., Litwin, M. S., Sandler, H. M., and Sanda, M. G. (2000). Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56, 899-905.
41. Zelefsky, M. J., Chan, H., Hunt, M., Yamada, Y., Shippy, A. M., and Amols, H. (2006). Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J. Urol. 176, 1415-1419.
42. Zelefsky, M. J., Leibel, S. A., Gaudin, P. B., Kutcher, G. J., Fleshner, N. E., Venkatramen, E. S., Reuter, V. E., Fair, W. R., Ling, C. C., and Fuks, Z. (1998). Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 41, 491-500.
43. Zelefsky, M. J., Shi, W., Yamada, Y., Kollmeier, M. A., Cox, B., Park, J., and Seshan, V. E. (2009). Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int. J. Radiat. Oncol. Biol. Phys. 75, 1350-1356.